Core Viewpoint - The company plans to adopt a new share option scheme and terminate the existing scheme, pending shareholder approval at the annual general meeting on April 24, 2025 [1][2] Group 1: Existing Share Option Scheme - The existing share option scheme was adopted on June 2, 2022, and is valid for ten years from the adoption date [1] - As of the announcement date, there are 355,968,000 share options granted under the existing scheme that remain unexercised [1] - The board does not intend to grant any further share options under the existing scheme until the annual general meeting [1] Group 2: New Share Option Scheme - The new share option scheme is proposed to attract and retain talented individuals within the group, providing additional incentives for eligible participants [2] - The new scheme aims to enhance the overall success of the group by offering eligible participants an opportunity to have personal stakes in the company [2] - The new share option scheme will comply with the revised Listing Rules effective from January 1, 2023, and will be valid for ten years from its adoption [1][2]
透云生物建议採纳新购股权计划及终止现有购股权计划